Tezepelumab Treatment Effect on Annualized Rate of Exacerbations by Baseline Biomarkers in Uncontrolled Severe Asthma Patients: Phase 2b PATHWAY Study

被引：0
|
作者：
Corren, J. [1 ]
Garcia Gil, E. [2 ]
Parnes, J. R. [3 ]
Pham, T. [4 ]
Griffiths, J. M. [4 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] AstraZeneca, Barcelona, Spain
[3] Amgen Inc, Thousand Oaks, CA 91320 USA
[4] MedImmune, Gaithersburg, MD USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2019年 / 199卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2621
引用
收藏
页数：2
相关论文
共 50 条
  • [1] EFFECT OF TEZEPELUMAB ON EXACERBATIONS IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA, ACCORDING TO BASELINE BODY MASS INDEX: RESULTS FROM THE PHASE 2B PATHWAY STUDY
    Ambrose, C. S.
    Colice, G.
    Salapa, K.
    Parnes, J. R.
    Corren, J.
    [J]. THORAX, 2021, 76 : A83 - A83
  • [2] THE EFFECT OF TEZEPELUMAB ON EXACERBATIONS IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA ACCORDING TO BASELINE INHALED CORTICOSTEROID DOSE: RESULTS FROM THE PHASE 2B PATHWAY STUDY
    Corren, Jonathan
    Ambrose, Christopher
    Salapa, Kinga
    Parnes, Jane
    Colice, Gene
    [J]. CHEST, 2020, 158 (04) : 30A - 31A
  • [3] Effect of Tezepelumab on Exacerbations in Patients with Severe, Uncontrolled Asthma, According to Baseline Body Mass Index: Results from the Phase 2b PATHWAY Study
    Ambrose, Chris
    Colice, Gene
    Salapa, Kinga
    Parnes, Jane
    Corren, Jonathan
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB25 - AB25
  • [4] Tezepelumab Reduces Multiple Key Inflammatory Biomarkers in Patients with Severe, Uncontrolled Asthma in the Phase 2b PATHWAY Study
    Pham, T.
    Ren, P.
    Parnes, J. R.
    Griffiths, J. M.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [5] Seasonal Variability of Exacerbations in Patients with Severe, Uncontrolled Asthma and Clinical Benefits of Tezepelumab: Results from the PATHWAY Phase 2b Study
    Corren, J.
    Karpefors, M.
    Hellqvist, A.
    Parnes, J. R.
    Colice, G.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [6] Seasonal variability of exacerbations in patients with severe, uncontrolled asthma and clinical benefits of tezepelumab: Results from the PATHWAY phase 2b study
    Corren, J.
    Karpefors, M.
    Hellqvist, A.
    Parnes, J. R.
    [J]. ALLERGY, 2020, 75 : 17 - 18
  • [7] Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study
    Corren, Jonathan
    Karpefors, Martin
    Hellqvist, Asa
    Parnes, Jane R.
    Colice, Gene
    [J]. JOURNAL OF ASTHMA AND ALLERGY, 2021, 14 : 1 - 10
  • [8] The Effect of Tezepelumab on Exacerbations in Patients with Severe, Uncontrolled Asthma According to Baseline Serum IL-5 and IL-13 Levels: Results from the Phase 2b PATHWAY Study
    Corren, J.
    Ambrose, C.
    Salapa, K.
    Parnes, J. R.
    Pham, T.
    Griffiths, J. M.
    Colice, G.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [9] Effects of Tezepelumab on Asthma Exacerbations and Type 2 Biomarkers in Patients with Severe, Uncontrolled Asthma with and Without Nasal Polyps: Results from a Post-Hoc Analysis of the Phase 2b PATHWAY Study
    Emson, C.
    Corren, J.
    Saapa, K.
    Hellqvist, A.
    Parnes, J. R.
    Colice, G.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [10] Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A Post Hoc Analysis of the Phase 2b PATHWAY Study
    Emson, Claire
    Corren, Jonathan
    Salapa, Kinga
    Hellqvist, Asa
    Parnes, Jane R.
    Colice, Gene
    [J]. JOURNAL OF ASTHMA AND ALLERGY, 2021, 14 : 91 - 99
12345